Patent 10233464 was granted and assigned to American Gene Technologies on March, 2019 by the United States Patent and Trademark Office.
The present invention relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include in vivo and/or ex vivo enrichment of HIV-specific CD4+ T cells.